医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ancillare Announces New Vice President of Asia-Pacific

2016年12月06日 PM09:00
このエントリーをはてなブックマークに追加


 

HORSHAM, Pa.

Ancillare, LP, the leader in end-to-end global clinical trial ancillary supply chain management services for pharmaceutical, biotechnology, contract research and medical research organizations, announced today the appointment of Nitin Jain to a new position as Vice President of the Asia-Pacific (APAC) region.

Nitin will focus on driving operational excellence to support our client’s clinical supply chain needs and oversee the complete end-to-end supply chain management operations of Ancillare’s Singapore Master Depot. Nitin brings to Ancillare over 18 years of business development, general management, strategic alliances, supply chain management and operations experience in pharmaceutical, biotechnology and contract research organizations around the world. Nitin has held senior positions at INC Research, Covance, Theorem Clinical Research and Worldwide Clinical Trials.

“We see significant growth potential in the APAC region. Nitin’s extensive experience and strong drive makes him a great fit to lead our operations and growth in the APAC region,” said Joanne Santomauro, Chief Executive Officer at Ancillare. By expanding our operations in Asia-Pacific this strengthens our ability to provide our clients with a single source for all their clinical trial supply chain needs.”

Singapore along with our strategic depots in China and Korea will provide Ancillare with the gateway to the entire APAC region by incorporating standard processes and procedures under one quality driven operation. The Singapore Operation will augment Ancillare’s strategic and master depot network so that our sponsors’ clinical operations leaders will have one point of expert contact and one clinical supply chain to manage all global trials needs from pre-protocol launch and first patient/first visit through last patient/last visit, site closeout and reclamation.

About Ancillare, LP

Ancillare, LP has extensive experience delivering cost savings and efficiencies to supply chains, with a complete turn-key approach for managing the pharmaceutical, biotechnology, contract research and medical research organizations’ clinical trial supply chains with a singular focus. Our turn-key global model (A-TKOTM) centralizes supply operations which accelerates the processes, lowers costs and mitigates risk by making clinical supply chains more efficient, cost-effective and global.

Our capabilities include pre-protocol analysis and planning, contribution to overall program feasibility assessments and timeline development, product sourcing and procurement, forecasting and budgeting, large and small equipment and consumables management, patient retention and recruitment materials, customs clearance, import/export (including IOR/EOR), storage, kitting, distribution and returns management/disposition (including destruction, refurbishment/recalibration and redeployment) on a global level.

Ancillare has master depots in United States, United Kingdom and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan and Ukraine. To learn more, visit ancillare.com or contact us via LinkedIn, Twitter and Facebook.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161206005053/en/

CONTACT

Ancillare, LP
Courtney Wright, 215-699-1700 ext. 107
Courtney.Wright@Ancillare.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表